Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com
Customer area
ITEN

Family · Pharmaceutical analytical standards

Infliximab

A chimeric monoclonal antibody, part mouse and part human, that neutralises TNF-alpha, a key driver of inflammation: created at New York University by Jan Vilček and Junming Le, it was approved in the United States in 1998 and is used for Crohn's disease, ulcerative colitis, rheumatoid arthritis and psoriasis. This family brings together the active ingredient.

Did you know?With the royalties from the medicine, Jan Vilček, born in Bratislava, set up a foundation with his wife Marica in 2000 that raises awareness of the contribution of immigrants to American life.

Go to the active ingredient →
Structure not applicable: biological materialActive ingredientInfliximab BRPCat. No. P-I047-001CAS 170277-31-3

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Structure not applicable: biological materialBiological preparationInfliximab BRPEDQM code Y0002110Family Infliximab
Structure not applicable: biological materialReference substanceInfliximab CRSEDQM code Y0002047Family Infliximab

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.

See our servicesContact us